Compare Nexgen Energy Ltd. Common Shares (NXE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nexgen Energy Ltd. Common Shares vs Repligen Corporation Common Stock — how do they compare? Nexgen Energy Ltd. Common Shares trades at $8.06 (market cap $5.67B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Nexgen Energy Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nexgen Energy Ltd. Common Shares for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| NXE | RGEN | |
|---|---|---|
Market Cap | $5.67B | $11.14B |
Volume | 4,335,942 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $13.92 | $194.57 |
52-Week Low | $7.56 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.42B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NexGen Energy (NXE) trades at $8.47, down 1.28% today, with a bearish technical signal from moving averages despite neutral oscillators. The company shows no current revenue but is advancing its Rook I uranium project targeting first production in 2030. Recent news highlights institutional buying and positive analyst sentiment amid expectations of long-term uranium supply deficits. Financials reflect pre-revenue development stage with negative profitability metrics and significant cash burn.
NXE presents a high-risk, high-potential opportunity as a pure-play uranium developer with strong analyst support but substantial execution risk. The bullish uranium market thesis contrasts with current financial losses and project development timelines. Investment appeal hinges on successful project financing and uranium price sustainability, with near-term volatility expected during construction phase.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nexgen Energy Ltd. Common Shares
NexGen Energy develops uranium projects in Canada. Its main asset is the Rook I Project in Saskatchewan, which includes the Arrow uranium deposit.
Read more on NXE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
